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Immune response against cancer is developed by innate effector cells and particularly relies on T cells, [1] which are sensitive to the level of tryptophan. [2] In the presence of cancer cells, tryptophan is degraded to kynurenine by indoleamine-2,3-dioxygenase (IDO), an essential enzyme in the kynurenine pathway. [3] The tryptophan metabolites or inadequate tryptophan consequently lead to T cell anergy, tilting the immune system toward tumor support. [4] Recently, small molecules have emerged to address IDO inhibition and revive T cells for cancer immunotherapy. [5] The front-runner of IDO inhibitors, D-1-methyl-tryptophan (D-1MT), has entered clinical trials against multiple types of cancers, [6] but the detailed mechanism of this weak IDO inhibitor is still controversial. [7] More specific and potent IDO inhibitors are in the pipeline. [8] Although IDO inhibitors as well as other immune checkpoint inhibitors have launched inspired clinical successes for cancer immunotherapy, satisfactory tumor regression has been only achieved in some patients with advanced cancer, while other patients do not respond, indicating a large room to further improve. [9] Some common chemotherapies are potentiated by IDO inhibitors. [10] For example, cisplatin, a first-line chemotherapeutic in clinics, [11] can induce more significant tumor regressions than single-agent therapy when combined with IDO inhibitors. [10] Besides, with the addition of cisplatin, the T cell-mediated antitumor immunity is enhanced by indirectly producing additional proinflammatory signals. [10, 12] Thus, a combination of cisplatin with IDO inhibitors may strengthen the dual advantages and overcome the limitations of immunotherapy and chemotherapy. Delivery of cisplatin together with IDO inhibitors will take advantage of not only the potential synergism from the two warheads but also delivery vehicles to achieve enhanced anticancer efficacy; however, the development of such an effective anticancer complex is still a nascent area.
Herein, we report an immuno-chemotherapeutic weapon for enhanced cervical cancer therapy. A nanohybrid ratiometrically co-loaded with IDO inhibitor and cisplatin prodrug was assembled, expected to be effective against cancer cells by killing them with cisplatin but simultaneously stimulating T cells to promote the apoptosis of cancer cells. This strategy of treating cervical cancer with immuno-chemotherapeutic nanomedicine to stimulate the function of T cells through IDO blocking might provide a new way of conquering cervical tumor especially that responds poorly to conventional chemotherapeutics.
To assemble a nanohybrid co-loaded with IDO inhibitors and chemotherapeutics, a reliable nanoparticle system is required. Layered double hydroxide (LDH) nanoparticles were utilized in our study, as they are biocompatible and biodegradable, with low toxicity and high cancer-cell selectivity. [13] We choose 4-{ [2-(4bromophenyl) hydrazinyl]sulfonyl}benzoic acid, a more potent IDO inhibitor (IDOi) than D-1MT, as the immune checkpoint inhibitor. [14] For chemotherapeutic regimen, a cisplatin prodrug c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2COOH) 2] (disuccinatocisplatin, DSCP) is utilized. In our design, the anionic property of both IDOi and the cisplatin prodrug ensures their efficient co-loading into the interlayer regions of LDH nanoparticles through anion exchange. More importantly, we take advantage of Pt(IV) prodrugs including lowered toxicity and efficient activation by intracellular reductants. [15] We expect that the nanohybrid enters cells through endocytotic pathways and the Pt(IV) prodrug is released from the nanohybrid and induces apoptosis in cancer cells; simultaneously, the IDOi discharges from the nanohybrid and boosts the T cell proliferation and immune response against cancer cells in a tumor microenvironment (Scheme 1).
Mg/Al LDH nanoparticles were fabricated through our previously established method. [16] Various ratios of DSCP and IDOi were subsequently co-loaded into LDH nanoparticles by anion exchange, and the loaded nanohybrid was designated as The nanohybrid was characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS) measurement. The TEM images illustrate the typical hexagonal morphology of LDH, Pt(IV)/LDH, and IDOi/LDH ( Figure S1 ). Apparently, for Pt(IV)-IDOi/LDH with different co-loading ratios (10:1, 1:2, 1:10, and 1:40), the nanohybrid remains the typical morphology of LDH. However, when the ratio of Pt(IV) to IDOi reaches 1:245, the nanohybrid aggregates and forms several clusters ( Figure S1 ). Therefore, the Pt(IV)-IDOi/LDH with the loading ratio of 1:245 was excluded from further investigation. With the successful insertion of Pt(IV) and IDOi into LDH nanoparticles, the decrease of zeta potential and the increase of hydrodynamic size are noted (Table S2 ). The gradual decrease of zeta potential is ascribed to the increased loading amount of negatively charged DSCP and IDOi, neutralizing the positively charged LDH. The average hydrodynamic size of LDH is 73.8 ± 2.1 nm, and the value steadily increases to 117. 2 ± 5.1, 158.2 ± 18.9, 176.9 ± 11.6, and 216.7 ± 30.8 nm for Pt(IV)-IDOi/LDH with Pt(IV):IDOi ratios of 10:1, 1:2, 1:10, and 1:40, respectively (Table  S2 ).
The cytotoxicities of the nanohybrid against HeLa and A549 cancer cells were determined. HCvEpC human cervical epithelial cells and WI-38 human lung fibroblast cells were included as comparisons (Table 1) . HeLa and A549 cells were chosen because the expression levels of IDO are higher in those cells especially the former than others including MCF-7, A2780, and A549cisR ( Figure S2 ). LDH nanoparticles themselves show negligible cytotoxicity with IC50 > 400 μg/mL in the two cell lines. Cisplatin shows typical IC50 values in the low micromolar range. Pt(IV)/LDH has a higher cytotoxicity than cisplatin, indicating the efficiency of the delivery system. The IC50 values of Pt(IV)-IDOi/LDH with a loading ratio of 1:2, 1:10, and 1:40 in HeLa cells are 1.5 ± 0.3, 0.7 ± 0.5, and 0.3 ± 0.1 μM, respectively. Clearly, Pt(IV)-IDOi/LDH exhibits more significant cytotoxicity in the cervical cancer cells. Moreover, the increased amount of IDOi enhances the cytotoxicity of the nanohybrid, which is likely from the inhibition of tryptophan degradation. [17] A similar trend is observed in A549 cells, and the Pt(IV)-IDOi(1:40)/LDH shows the highest cytotoxicity in the sub-micromolar range. In contrast, the nanohybrid is not significantly active in IDO-expressing HCvEpC and WI-38 cells ( Figure S2 ). The cytotoxicity of Pt(IV)-IDOi(1:40)/LDH toward HCvEpC cells is 26-time lower than that in HeLa cells, while the cytotoxicity in WI-38 cells shows 16-time lower than that in A549 cells, suggesting the high cancer-cell selectivity of the nanohybrid. Since Pt(IV)-IDOi(1:40)/LDH shows the highest cytotoxicity in the IDO-expressing HeLa cells, we utilize this sample and the cervical cancer cells for the following biological assays.
Cancer cells can be disguised by kynurenine and are able to evade from the immune system via IDO-mediated tryptophan pathway. [18] Hence, the capacity of Pt(IV)-IDOi(1:40)/LDH to block kynurenine production in HeLa cells was examined. An Ehrlich's reagent (2% p-dimethylaminobenzaldehyde) was utilized to react with kynurenine, and the level of this tryptophan metabolite was quantified. [19] The half maximum effect concentration (EC50) shown in Table S3 and the level of kynurenine in Figure S5 represent the inhibitory efficacy of kynurenine production in HeLa cells. D-1MT has an EC50 value of >1 mM, confirming its weak inhibitory effect. The IDOi we use shows a stronger inhibitory effect than D-1MT against the catalytic activity of IDO in HeLa cells with an EC50 value of 163 ± 24 μM. In contrast, IDOi/LDH is very effective in blocking the kynurenine production, and its EC50 value is 4.0 ± 0.3 μM, indicating the efficient delivery of IDOi into the cells. Intriguingly, Pt(IV)-IDOi(1:40)/LDH shows the highest activity with an EC50 value of 1.9 ± 0.2 μM against kynurenine 
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production, showing the effectiveness of the nanohybrid to inhibit IDO.
With the reduction of kynurenine production, T cells can proliferate to boost anti-tumor immune responses. [20] Mixed leukocyte reactions (MLRs) is applied for measuring the cellular immune response in vitro. Human peripheral blood mononuclear cells (PBMCs) were employed to mimic the immune microenvironment in the body because it consists of lymphocytes and monocytes. [21] A double-staining flow cytometric assay was applied for the detection of T cell proliferation. In the experiment, PBMCs from unrelated healthy donors were stimulated by phytohemagglutinin-M (PHA-M), a lectin, for T cell activation. The cells were subsequently stained with carboxyfluorescein succinimidyl ester (CFSE), a fluorescent cell staining dye without adverse effect to cell health, and co-cultured with adherent HeLa cells. The HeLa/MLRs were treated with the complexes, and PBMCs were harvested and stained with a FITC-conjugated anti-CD3 antibody. Here, CD3 acts as a marker representing the development of T cells, which is also required for T cell activation. [22] After treatment, CFSE-labeled and CD3 + dualpositive T cells were analyzed for the changes of proliferating T cells. The depleting of IDO enzyme induced by our nanohybrid may lead to T cell proliferation in this HeLa/MLRs system.
When HeLa cells are mixed with PBMCs without any treatment, the percentage of T cell proliferation is as low as 5.6% ( Figure 1A ). In the group containing a mixture of D-1MT and cisplatin, 29.8% of T cells proliferate, and the value increases to 35.3% for a mixture of IDOi and cisplatin, indicating the effectiveness of IDOi in stimulating T cell activity ( Figure 1B and 1C). Remarkably, HeLa/MLRs treated with Pt(IV)-IDOi(1:40)/LDH have 41.9% of T cell proliferation, which is higher than the results from the control or the co-treatment without nanocarrier, showing that our nanohybrid can effectively stimulate the proliferation of T cells ( Figure 1D ). The subsequent generation of divided T cells was then analyzed based on the increasing dilution of CFSE. Each additional peak, shown in the pink color in Figure 1 , indicates one subsequent generation of T cells. After 6 days, the HeLa/MLRs incubated with Pt(IV)-IDOi(1:40)/LDH apparently show more T cell generations than all the other groups, further confirming the proliferation of T cells. Together with the cytotoxicity results above, it is obvious that our nanohybrid is an effective immuno-chemotherapeutic agent that can simultaneously kill cervical cancer cells and stimulate T cell proliferation.
The above-mentioned HeLa/MLRs system only corroborates the proliferation of T cells, but the subsequent effect on cancer cells is still unknown. To know this, cell cycle distribution of HeLa cells in the presence of PBMCs after treatment with Pt(IV)-IDOi/LDH was measured. HeLa cells without treatment display a normal profile of cell cycle distribution (Figure 2A ). The cells treated with Pt(IV)-IDOi/LDH without the presence of PBMCs are arrested at the S phase (43.2%), and we attribute this cell cycle arrest to the efficient delivery of cisplatin prodrug into HeLa cells to arrest the cell cycle. In contrast, our nanohybrid arrests the HeLa cells at the S phase more strongly in the presence of PBMCs. Under this condition, 67.6% of the cells stay at the S phase, indicating the role of activated T cells in arresting the cell cycle of HeLa cells, possibly through the blockage of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) ligands. [23] The apoptotic level of HeLa cells after T cell proliferation and activation in the HeLa/MLRs co-culture system was further examined. HeLa or HeLa/MLRs cells were exposed to Pt(IV)-IDOi/LDH, and HeLa cells were subsequently harvested and stained with Annexin V-FITC/7-AAD for flow cytometric analysis. For untreated group, the fractions of early apoptotic and late apoptotic cells are 2.6% and 14.1%, respectively ( Figure 2B ). In Pt(IV)-IDOi/LDH-treated group, the values significantly increase to 39.7% and 23.6% for early apoptosis and late apoptosis, respectively, indicating that our nanohybrid is able to effectively induce apoptosis in HeLa cells due to the presence of the chemotherapeutic warhead ( Figure 2C ). Particularly, when the cells were treated with the same concentration of the nanohybrid in the presence of PBMCs, significant escalation of late apoptosis (53.9%) was observed ( Figure 2D ). Apoptotic induction ability of the nanohybrid was further illustrated by labeling the fragmented DNA with the use of a TUNEL assay. Apoptosis occurred in HeLa cells treated with the nanohybrid in and without the presence of PBMCs ( Figure S6 ). Apparently, the presence of PBMCs results in a higher level of apoptosis (50.2%) compared with the nanohybrid alone (33.9%) ( Figure S7 ). Therefore, the presence of COMMUNICATION activated T cells accelerates the apoptosis of the cervical cancer cells. Collectively, the data suggest that T cell activation is able to arrest the cell cycle and promote apoptosis in cancer cells when treated with our nanohybrid. The antitumor activity of our nanohybrid in vivo was further demonstrated. Because BSA-coated LDH nanoparticles have shown great biocompatibility in vivo, [24] we prepared BSA-coated Pt(IV)-IDOi(1:40)/LDH. The shape, size, and zeta potential of the BSA-coated nanohybrid do not change significantly after 24 h incubation in blood plasma (Figures S11, S12, and Tables S4, S5 ). The BSA-coated nanohybrid was then used for an anticancer efficacy test in nude mice bearing HeLa xenograft. To verify the immuno-chemotherapeutic function of our nanohybrid, PHA-Mstimulated PBMCs were intravenously (i.v.) injected into two groups of mice to engraft human immune system in the immunodeficient mice after the HeLa tumor nodules were palpable. [25] Twenty four hours after PBMCs injection, BSAcoated Pt(IV)-IDOi(1:40)/LDH or PBS were injected (i.v.) for total 4 times at one day interval (Figures 3 and S13). After 14 days, BSA-coated Pt(IV)-IDOi(1:40)/LDH exhibits significantly stronger tumor inhibition than the other two groups (p < 0.001). Notably, the size of tumors in the group of PBMCs with the nanohybrid (291.7 ± 125.6 mm 3 ) is significantly smaller than the one in the group treated with the nanohybrid only (662.2 ± 168.5 mm 3 ) (p < 0.05), suggesting the effectiveness of our immunochemotherapeutic warhead in the presence of PBMCs. The body weight of each group increases gradually, indicating the safety of our nanohybrid ( Figure S14 ). The level of free kynurenine and tryptophan in tumors was quantified by HPLC. Both the level of kynurenine and the ratio of kynurenine to tryptophan significantly decrease in the nanohybrid-treated groups compared with the untreated ones ( Figure S15 ), revealing the inhibition of IDO by the nanohybrid in vivo. These results further confirm the efficacy of the nanohybrid in immune-chemotherapy in vivo.
In summary, we report the first example of a nanohybrid system bearing both IDOi and cisplatin as an immunechemotherapeutic weapon to significantly boost the antitumor activity of cisplatin against cervical cancer. The nanohybrid containing chemotherapeutic regiments displays dramatically increased capability to kill HeLa cells without the presence of PBMCs, with a 17-fold increase in cytotoxicity compared with cisplatin alone. Remarkably, the presence of PBMCs in the system significantly boosts the antitumor activity of the nanohybrid, evidenced by the activation of T cells, the cell cycle arrest of HeLa cells induced by T cells, and the significantly increased fraction of late apoptotic HeLa cells resulted from the T cell activation. Compared with a small-molecule conjugate of D-1MT and cisplatin, [26] our nanohybrid apparently has many advantages, such as capability of tuning the ratio of IDOi and cisplatin to maximize the effectiveness of the system, limited premature reduction of cisplatin prodrug protected by nanoparticles, [27] cancer cell specificity, and potential passive tumor targeting due to the enhanced permeability and retention (EPR) effect. Our nanohybrid is, therefore, a very powerful antitumor complex utilizing a combinatorial strategy of both chemotherapy and immunotherapy, conveying a drug delivery system based on nanoparticles to overcome the current issues of efficient cancer therapy. Mean ± SD, n = 5. .............................................................................................................................................. 
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Experimental Details
Materials and general instruments
All the related chemicals were acquired from commercial resources, except the IDO inhibitor was prepared following the reported protocols [1] and characterized by 1 
Synthesis of Pt(IV)/LDH, IDOi/LDH, Pt(IV)-IDOi/LDH
Bromophenyl)hydrazinyl]sulfonyl}benzoic acid (IDOi) and layered double hydroxides (LDH) were prepared following the reported literatures [2] and our previous work, [3] respectively. Pt(IV)/LDH was synthesized as the previous reports [4] . Briefly, 1.5 mL DSCP (5 mM, pH 8.0) and LDH were stirred together overnight, and the synthesized suspension was washed twice with Milli-Q water for further study. For the synthesis of IDOi/LDH, IDOi (20 mM, 1.325mL, pH 8.0) was added to a suspension of LDH nanoparticles (4.0 mg/mL, 1.0 mL) and stirred overnight in dark. The complex was then washed twice with 12,000 × g centrifugation for 10 min and resuspended in Milli-Q water. Pt(IV)-IDOi/LDH with different ratios of Pt(IV) and IDOi were synthesized through a similar process. 500 μL DSCP (5 mM) and various amount of IDOi were added in LDH nanoparticles suspension before stirred overnight. All the prepared samples were stored at 4C in dark.
Characterization of nanoparticles
The Pt content in the nanoparticles was determined by Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES, PerkinElmer, Optima 8000). UV-vis spectroscopy (Shimadzu, UV-1700 PharmaSpec, UV-vis Spectrophotometer) was applied to quantify the amount of IDOi in the nanoparticles. Transmission Electron Microscopy (TEM, Philips Technai 12) was employed for morphology analysis. The size distribution and zeta potential were measured by dynamic light scattering (DLS) on Malvem Zetasizer Nano ZS.
Pt and IDOi content in nanoparticles
Pt release level in each sample (100μL) was digested by 400 μL concentrated nitric acid overnight, then the mixture was diluted with 500 μL DI water before ICP-OES measurement. The nanoparticles (100 μL) were pretreated with 0.1 N HCl
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(900 μL) overnight to break down LDH and to release free IDOi before UV-vis spectroscopy measurements. The absorbance peak of IDOi at 230 nm was employed to calculate the concentration of IDOi in the digested solution.
Cell lines and cell culture conditions
HeLa, MCF-7, A549 and A549cisR cells were maintained in DMEM with 10% FBS and 50 U/mL penicillin and streptomycin. A2780 cells were maintained in RPMI 1640 with 10% FBS, 2 mM L-glutamine and 50 U/mL penicillin and streptomycin. WI-38 cells (human lung fibroblast) were maintained in MEM with 10% FBS, 1% L-glutamine, 1% NEAA and 1% sodium pyruvate. Human cervical epithelial cells (HCvEpC) were obtained from Cell Applications, Inc., and maintained in Epithelial Cell Growth Medium (Cell Applications, Inc., USA). A kind of special medium (10% dextrose, 40% RPMI and 50% FBS) was applied to thaw the PBMCs and the cells were consequently cultured in RPMI complete culture medium (20% FBS). To mimic in vivo circumstances, the processes to change the medium in PBMCs culture flask were modified as described: half of the culture medium was taken out from the flask, then the supernatant was discarded after centrifugation, the cell pellet was resuspended in fresh medium and mixed with the original half volume of PBMCs in the flask. With the purpose of keeping some growth factors or cytokines inside, the procedure will lose a few PBMCs after medium changed undoubtedly. All the cells were grown in a humidified incubator at 37˚C with 5% carbon dioxide. milk Tris buffer saline for 3 to 5 times. After incubation of horseradish peroxidase conjugated secondary antibody (Thermo Scientific) for 1h, the membrane was washed with TBST for 3 to 5 times, followed by ECL reagent (Thermo Scientific) and imaged with Bio-Red ChemiDoc TM Touch Imaging System.
Western blotting
MCF
Cell viability tests
MTT assay was employed to measure the cell viability. HeLa, A549, WI-38 cells (3 × 10 3 cells/well) and HCvEpC (6.5 × 
Cellular accumulation of platinum in HeLa cells
S5
HeLa cells were seeded in 10 cm petri dishes and incubated until the cell confluency reached 80%. The medium was changed to fresh medium containing cisplatin, cisplatin with IDOi (1:40), Pt(IV)/LDH and Pt(IV)-IDOi(1:40)/LDH at the concentration of 5 and 10 μM Pt. After 8 h, cells were collected and washed with ice-cold PBS for 3 times. Cell pellet was resuspended in 1 mL PBS. The cells were then digested by 30% conc. nitric acid overnight at 65˚C, and the Pt content was measured by ICP-OES. The platinum level in cells was expressed as ng Pt per 10 6 cells.
Pt level in Genomic DNA
HeLa cells were seeded in 10 cm petri dishes and incubated until the cell confluency reached 80%. The medium was changed to fresh medium containing cisplatin, cisplatin with IDOi (1:40 
Cell-based kynurenine assay
HeLa cells were seeded in 48-well plates at a density of 3×10 50˚C. The microplates were then centrifuged for 10 min at 3,000  g to remove the sediments. 100 μL of the supernatant was mixed with 100 μL of 2 % (w/v) p-dimethylaminobenzaldehyde in acetic acid and measured at 480 nm in a microplate reader. The concentration of kynurenine in each sample was quantified from a kynurenine standard curve.
T cell proliferation in HeLa/MLRs
HeLa cells were seeded with a density of 1×10 3 cells/well in 6-well plates. Twenty-four hours after the HeLa cells cultivation, the medium in each well was replaced with 2 mL fresh complete DMEM containing various concentrations of complexes, 50 ng/ml IFN-γ and 0.1 mM L-tryptophan. The HeLa cells were exposed to different complexes for 2 
Cell cycle analysis for HeLa cells
HeLa cells were cultured in 6-well plates with a density of 3 × 10 3 cells/well. 1 × 10 5 PBMCs were added into the HeLa cells with or without compounds ([Pt] = 5 μM). After 6 days of incubation, suspended PBMCs were removed and the HeLa cells were washed twice with PBS for cell cycle analysis. HeLa cells were then harvested and washed twice with PBS with centrifugation, 1,500 rpm/5 min. The cell pellets were resuspended in 0.5 mL PBS and fixed in 5 mL ethanol (70%) at 4˚C overnight. Then the fixed cells were washed after centrifugation, and resuspended in 1 mL PI solution (0.1% Triton X-100, 200 μg/mL RNase A, 20 μg/mL propidium iodide, pH 7.4). The cells were incubated at 37C for 30 min in dark. Cell cycle distribution was analyzed by a BD flow cytometer with excitation at 488 nm and emission at 632 nm.
The data were analyzed by a FlowJo 7.6.1 software.
Apoptosis analysis in HeLa cells using flow cytometry
HeLa cells were seeded in 6-well plates at a density of 1 × 10 4 cells per well and incubated for 24 h. Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) were added with/without PHA-M activated PBMCs (3 × 10 5 cells/well). After 72 h of incubation, HeLa cells were harvested for apoptosis analysis. The cells were subsequently washed with cold PBS and annexin binding buffer, and the cell density was determined and adjusted to 1 × 10 6 cells per mL. Annexin V conjugated FITC and 7-AAD solution were added to 100 μL cells suspension. The cells were stained at RT for 15 min, then 400 μL annexin binding buffer was added and mixed gently. The as-prepared samples were kept on ice and analyzed by flow cytometer with excitation at 488 nm and emission at 532 nm and 650 nm for FITC and 7-AAD, respectively.
Apoptosis analysis in HeLa cells using TUNEL
HeLa cells (1 x 10 4 ) were seeded on slides and incubated for 24h before Pt(IV)-IDOi(1:40)/LDH ([Pt] = 5 μM) were added with/without PHA-M activated PBMCs (3 × 10 5 ). After 3 days of incubation, HeLa cells on the slides were fixed in 4% formaldehyde in PBS for 25 min at 4˚C, and washed twice in PBS. Sides were immersed in 0.2% Triton X-100 in PBS for 5 min for permeabilizing cells. Then cells equilibrated with 100 μL Equilibration Buffer at room temperature for 5-10 S7 min, and labeled with 50 μL TdT reaction mix (45 μL Equilibration Buffer, 5 μL Nucleotide Mix and 1 μL rTdT Enzyme) at 37˚C for 60 min in a humidified chamber. Slides were protected from light since this step forward. Stop label reaction by immersing slides in 2 X SSC buffer, slides were washed three times with PBS to remove unincorporated fluorescein-12-dUTP. To visualize all nuclei, freshly prepared PI working solution (1 μg/mL propidium iodide, in PBS) was applied to counterstain all samples. Samples were immediately analyzed under a motorized fluorescence microscope (Nikon Eclipse 90i). Apoptotic cells with green fluorescence were detected at 520 nm, and the nuclei with red fluorescence were viewed at 620 nm. ImageJ software was used for quantification. For the TUNEL result, the apoptotic index was expressed as the percentage of TUNEL-positive cells out of the total number of cells counted.
Pt accumulation in HeLa, PBMCs, T cells and medium for delivery efficiency test
HeLa cells (1 x 10 4 ) were seeded in 6-well plates and incubated for 24h following the addition of Pt(IV)-IDOi ( 
Preparation of BSA-coated nanohybrid
Albumin-coated nanoparticles were synthesized for the in vivo experiment [5] . In brief, 5 mL suspension of as-prepared Pt(IV)-IDOi(1:40)/LDH was added into 5 mL BSA stock solution (10 mg/mL) dropwise with the albumin/ LDH mass ratio of 5 : 2 under vigorous stirring. The reaction was stirred for 30 min and protected from light. After the reaction, the BSAcoated nanohybrid was washed 3 times with PBS and re-suspended in PBS for in vivo experiment.
Characterization of nanohybrid and BSA-coated nanohybrid in blood plasma
Whole blood was collected from healthy BALB/c nude mice into the EDTA-treated microtube. Then the cells were removed from plasma by centrifugation for 15 min at 2,000 x g, 4˚C.
To check the characterization of nanoparticles in blood plasma, centrifuged nanoparticles or BSA-coated nanoparticles (12,000 x g, 10 min) were dispersed in 300 μL mice blood plasma. After 5 s of vortex, 100 μL of blood plasma and nanohybrid mixture were taken out and washed twice with PBS (12,000 rpm, 10 min) for characterization at 0 h. The rest mixture was maintained in 37 ˚C for 24 h. TEM, size distribution and zeta potential of the samples were taken for the characterization
In vivo anti-tumor efficacy in subcutaneous HeLa xenograft mouse model
To evaluate the immune-chemotherapeutic nanohybrid, an anti-tumor efficacy model was established on BALB/c background nude mice. The HeLa cervical cancer cells (5 × 10 5 cell / 0.1 mL / mouse) were subcutaneously implanted in the right axillary fossa of BALB/c nude mice (6-week-old, 18 -23 g body weight) to establish the xenograft mouse S8 model. Tumor nodules were allowed to grow 7 days to achieve a diameter of 5 -8 mm before treatment initiation. All the mice were numbered with ear tags. The treatment phase included intravenously injection of PHA-M-activated normal
PBMCs (approximately 5 x 10 6 cell / 0.1 mL / mouse), followed on intravenously injection of BSA-coated Pt(IV)-IDOi(1:40)/LDH ([Pt] = 0.5 mg/kg) and PBS as a negative control ( Figure S12 ). The BSA-coated nanohybrid was injected every two days for total four times of injection. Since HeLa cells grow aggressively in nude mice, the experiment is terminated on Day 14. The tumor dimension and body weight were measured every two days for 14 days of duration.
Tumor length and width were measured with calipers, and the tumor volume was calculated using the following equation:
TV=(a)(b 2 )π/6, where a is the longest dimension and b is the largest dimension orthogonal to a. Statistical analysis was performed using Student's t-Test at the end point.
Determination of tryptophan and kynurenine level in tumor by high-pressure liquid chromatography (HPLC)
All the mice in each group were sacrificed after experiment terminated, tumors were harvested and frozen at -80 ˚C after washed in phosphate-buffered saline. The total free tryptophan and kynurenine in tumors were quantified by HPLC [6] .
The tumors were homogenized with ice-cold 0.16 M perchloric acid containing 0.1% EDTA and 0.1% ascorbic acid for 5 min and centrifuged at 20,000 x g for 20 min, and the supernatant was filtered for HPLC. The chromatography was performed in a Shimadzu LC-20AT liquid chromatograph with a 250-by 4.6-mm (inner diameter) C18 reverse-phase column (Phenomenex, Gemini 5 μ C18 110A). In tryptophan measurement, the column was eluted at a flow rate of 1.0 ml/min with 0.015 M sodium acetate (pH 4.5) containing 15% methanol for analysis of tumor samples. For kynurenine determination, the column was eluted with acetonitrile at a 1:47 dilution in 0.1 M acetic acid-0.1 M ammonium acetate (pH 4.65) . The absorbance of the column effluent was monitored at 280 and 365 nm for tryptophan and kynurenine, respectively. The peaks of tryptophan or kynurenine were identified by comparison with the retention time of standard compounds (Sigma), and quantification was based on the ratios of the peak areas of the compound to the standard.
Animal ethics
All BALB/c nude mice were purchased from the Chinese University of Hong Kong and maintained under pathogen-free conditions in the City University of Hong Kong. The studies involving animal all in accordance with the protocol and was approved by the Institutional Animal Ethics Committee.
Statistical analysis
All the results were expressed as Mean ± SD where applicable. GraphPad Prism 6 software (GraphPad Software) was used for statistical analysis. All the results are expressed as Mean ± SD. The possibility of unintended or off-target effects of the nanohybrid was further investigated in the co-culture system.
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Results
Cell viability of PBMCs was first tested in different treatment conditions using an MTS assay ( Figure S8 ). The cell viabilities of PBMCs do not significantly change after exposure to the nanohybrid ([Pt] = 1 or 5 μM) for 3 days in and without the presence of HeLa cells, indicating that our nanohybrid hardly affects the viability of T cells, the major component of PBMCs. [7] Distributions of the nanohybrid in HeLa cells and PBMCs were quantified ( Figures S9 -S10 ).
After treatment for 72 h ([Pt] = 5 μM), the percentage of Pt in HeLa cells, PBMCs, and supernatant is 27.0%, 4.6%, and 68.4%, respectively ( Figure S9A) , indicating that the nanohybrid is able to efficiently deliver Pt into HeLa cells rather than PBMCs. injection. The body weight of each group was measured every two days for 14 days of duration. Mean ± SD, n = 5.
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S23 Figure S15 . Concentration of free kynurenine and tryptophan in tumor samples from in vivo experiment using HPLC.
Concentrations of A) kynurenine, B) tryptophan, C) ratio of kynurenine / tryptophan were calculated by using D) kynurenine standard curve, and E) tryptophan standard curve.
The UV detector in HPLC was set at 365 and 280 nm to measure kynurenine and tryptophan levels, respectively. *** p < 0.001. Mean ± SD, n = 5. 
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